Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2010 Mar 1.

Published in final edited form as: Mol Cancer Ther. 2009 Mar 3;8(3):703–710. doi: 10.1158/1535-7163.MCT-08-0656

a) Planar images of K562 xenografts 24 or 48 hours after injection of ¹¹¹In -EC-BSA or ¹¹¹In -EC-APT before and after 4 or 5 day imatinib treatment. b) Average tumor to muscle count density ratios of ¹¹¹In-EC-BSA and ¹¹¹In EC-APT before and after 4 or 5 day imatinib therapy of K562 xenografts (n = 5 in each group). Data shows 24 and 48 hours after injection of ¹¹¹In-labeled antibodies. Mice injected with ¹¹¹In-EC-APT had higher tumor/muscle count density ratios than mice treated with ¹¹¹In-EC-BSA (p<0.05). Furthermore, after treatment with 4 or 5 days of imatinib, respectively, tumor/muscle count density ratios are markedly decreased (p<0.05, student’s t test).

a) Planar images of K562 xenografts 24 or 48 hours after injection of ¹¹¹In -EC-BSA or ¹¹¹In -EC-APT before and after 4 or 5 day imatinib treatment. b) Average tumor to muscle count density ratios of ¹¹¹In-EC-BSA and ¹¹¹In EC-APT before and after 4 or 5 day imatinib therapy of K562 xenografts (n = 5 in each group). Data shows 24 and 48 hours after injection of ¹¹¹In-labeled antibodies. Mice injected with ¹¹¹In-EC-APT had higher tumor/muscle count density ratios than mice treated with ¹¹¹In-EC-BSA (p<0.05). Furthermore, after treatment with 4 or 5 days of imatinib, respectively, tumor/muscle count density ratios are markedly decreased (p<0.05, student’s t test).